Transoma gets FDA approval for cardiac device

"Transoma Medical Inc. has received U.S. Food and Drug Administration approval for its Sleuth AT implantable cardiac-monitoring system, the follow-up to its original Sleuth product that launched in 2007. The Sleuth products help physicians diagnose patients with recurrent, unexplained fainting and abnormal heart rhythms more quickly, while also minimizing paperwork and practice workload, Transoma said in a press release Wednesday. Sleuth AT allows physicians to use the program with electrocardiogram (ECG) data to help monitor the efficacy of prescribed therapies. The products can be used to detect cardiac arrhythmias such as atrial fibrillation, ventricular tachycardia, bradycardia and supraventricular tachycardia. Atrial fibrillation is the most common arrhythmia, affecting approximately 2.2 million Americans." - American City Business Journals,